Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

69 comunicati stampa

Guarda tutti i comunicati
16/05/2026
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Web e Social Network
Mercato del lavoro
Eventi
Industria
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Mercato azionario
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Mercato del lavoro
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
09/04/2026
Mercato azionario
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
06/04/2026
Oncologia
Advertising
Salute
Comunicazione
Igiene alimentare
Farmaceutica
Biotecnologia
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
31/03/2026
Industria
Biotecnologia
Farmaceutica
Salute
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
26/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
20/03/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
17/03/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0